期刊
BLOOD PURIFICATION
卷 41, 期 1-3, 页码 11-17出版社
KARGER
DOI: 10.1159/000439581
关键词
Dialysis; Continuous renal replacement therapy; Catheters; Femoral vein; Intensive care
资金
- National Health and Medical Research Council (NHMRC) of Australia [352550]
- Health Research Council (HRC) of New Zealand [06-357]
- Australian National Health and Medical Research Council
- Roche
- Gambro
- Karolinska Institutet
- Servier
- Novartis
- Eisai
- Merck
- Sharp Dohme
- Pfizer Australia
- Fresenius Kabi Deutschland GmbH
- Sanofi Aventis
Aims: The study aims to describe the use of dialysis catheters in critically ill patients treated with continuous renal replacement therapy (CRRT) and to study the impact of femoral versus non-femoral access on CRRT dose. Methods: Statistical analysis and predictive modelling of data from the Randomized Evaluation of Normal vs. Augmented Level renal replacement therapy trial. Results: The femoral vein was the first access site in 937 (67%) of 1,399 patients. These patients had higher Acute Physiology and Chronic Health Evaluation and Sequential Organ Failure Assessment scores (p = 0.009) and lower pH (p < 0.001) but similar mortality to patients with non-femoral access (44 vs. 45%; p = 0.63). Lower body weight was independently associated with femoral access placement (OR 0.97, 95% CI 0.96-0.98). Femoral access was associated with a 1.03% lower CRRT dose (p = 0.05), but a 4.20% higher dose was achieved with 13.5 Fr catheters (p = 0.03). Conclusions: Femoral access was preferred in lighter and sicker patients. Catheter gauge had greater impact than catheter site in CRRT dose delivery. Video Journal Club Cappuccino with Claudio Ronco at http://www.karger.com/?doi=439581. (C) 2015 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据